Drug

Radiation Therapy

CI-DRUG-00000504Explore in graph →NCIt C15313 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	7	3	2	14	—	—	2001-02
Malignant Nasopharyngeal Neoplasm	Phase3	Phase 3	1	1	1	1	—	—	Jan 1, 2022
Malignant Central Nervous System Neoplasm	Phase3	Phase 3	0	0	1	1	—	—	2001-02
Non-Hodgkin Lymphoma	Phase2	Phase 2	3	1	0	3	—	—	Feb 4, 2019
Malignant Lung Neoplasm	Phase2	Phase 2	1	0	0	2	—

Curated evidence

Clinical evidence (6)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AURKA EXPRESSION1
Cisplatin + Fluorouracil

Clinical trials

Trials with this intervention (14)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–14 of 14 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07843537	MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study	not yet recruiting	Phase 2	30	M.D. Anderson Cancer CenterOTHER	1	Sep 28, 2026	clinicaltrials
NCT02905591	A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC(XACT-LUNG)

EGFR Overexpression1
Gefitinib + Radiation TherapyCombination	Glioma	Predictive	D	Supports Sensitivity Response	3	submitted	EID7803 Study of malignant glioma cells with EGFR amplification, IGRG88. IGRG88 cells showed a 946 fold increase of EGFR mRNA when compared to IGRG119, a tumor known to express low levels of EGFR mRNA. IHC … (full text at CIViC) PMID 18386816 · Geoerger et al., 2008 · Open in CIViC	civic

EGFR Overexpression1

Gefitinib + Radiation TherapyCombination

Glioma

Predictive

Supports Sensitivity Response

submitted

EID7803

Study of malignant glioma cells with EGFR amplification, IGRG88. IGRG88 cells showed a 946 fold increase of EGFR mRNA when compared to IGRG119, a tumor known to express low levels of EGFR mRNA. IHC … (full text at CIViC)

PMID 18386816 · Geoerger et al., 2008 · Open in CIViC

civic

CD274 Expression1
Radiation Therapy	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	4	accepted	EID3000 Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamo… (full text at CIViC) PMID 28476872 · Skinner et al., 2017 · Open in CIViC	civic

CD274 Expression1

Radiation Therapy

Head and Neck Squamous Cell Carcinoma

Predictive

Supports Resistance

accepted

EID3000

Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamo… (full text at CIViC)

PMID 28476872 · Skinner et al., 2017 · Open in CIViC

civic

PIK3CA Mutation1
Radiation Therapy + TaselisibCombination	Head and Neck Squamous Cell Carcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1490 A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensiti… (full text at CIViC) PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC	civic

PIK3CA Mutation1

Radiation Therapy + TaselisibCombination

Head and Neck Squamous Cell Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID1490

A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensiti… (full text at CIViC)

PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC

civic

STK11 Mutation1
Radiation Therapy	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	4	submitted	EID12912 In retrospective analyses of multiple non‑metastatic NSCLC cohorts (TCGA PanCancer n = 736, MSK‑IMPACT n = 961, TRACERx n = 100), pathogenic STK11 mutations were associated with worse outcomes only in… (full text at CIViC) PMID 35958336 · Kinslow et al., 2022 · Open in CIViC	civic

STK11 Mutation1

Radiation Therapy

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Resistance

submitted

EID12912

In retrospective analyses of multiple non‑metastatic NSCLC cohorts (TCGA PanCancer n = 736, MSK‑IMPACT n = 961, TRACERx n = 100), pathogenic STK11 mutations were associated with worse outcomes only in… (full text at CIViC)

PMID 35958336 · Kinslow et al., 2022 · Open in CIViC

civic

BRAF V600E1
Radiation Therapy + VemurafenibCombination	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	submitted	EID3743 A 51 year old male anaplastic thyroid cancer patient harboring BRAF V600E experienced rapid improvement in response to vemurafenib. The patient was initially treated with paclitaxel and carboplatin bu… (full text at CIViC) PMID 23406047 · Rosove et al., 2013 · Open in CIViC	civic

BRAF V600E1

Radiation Therapy + VemurafenibCombination

Thyroid Gland Anaplastic CarcinomaALIAS

Predictive

Supports Sensitivity Response

submitted

EID3743

A 51 year old male anaplastic thyroid cancer patient harboring BRAF V600E experienced rapid improvement in response to vemurafenib. The patient was initially treated with paclitaxel and carboplatin bu… (full text at CIViC)

PMID 23406047 · Rosove et al., 2013 · Open in CIViC

civic